// App-Quantinova.ai

: CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Researchers

Presenter

  • Fabian Mueller

Principal Investigators

  • Simon Voelkl

  • Dimitrios Mougiakakos

  • Sebastian Boeltz

  • Michael Aigner

  • Regina Gary

  • Sascha Kretschmann

  • Soraya Kharboutli

  • Arnd Kleyer

  • David Simon

  • Wolf Rosler

  • Katharina M. Habenicht

  • Thomas H. Winkler

  • Gerhard Kronke

  • Georg Schett

  • Andreas Mackensen

Medical Centers

  • Department of Internal Medicine - Hematology/Oncology, University Hospital of Erlangen, Erlangen, Germany

  • Department of Biology, Divison of Genetics, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

  • Otto von Guericke University Magdeburg, Magdeburg, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Glomeruloid microvascular proliferation

Drug/Treatment

  • Hydroxychloroquine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Prednisolone

  • fludarabine tablet

  • Belimumab

  • Rituximab

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Multinational

  • Tolerability

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved